About
AI-enabled metabolic cancer immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalAI FocusedChina
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
1
As Collaborator
9
Total Enrollment
367
By Phase
EARLY_PHASE1: 9NA: 1
By Status
RECRUITING: 7UNKNOWN: 2COMPLETED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07106814Collaborator
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
EARLY_PHASE1Recruiting
36 participants
Started: Aug 29, 2025 · Completed: Dec 30, 2027
NCT07085559Collaborator
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
EARLY_PHASE1Recruiting
36 participants
Started: Jun 23, 2025 · Completed: Oct 15, 2027
NCT06711146Collaborator
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
EARLY_PHASE1Recruiting
36 participants
Started: Feb 10, 2025 · Completed: Apr 5, 2027
NCT06716164Collaborator
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
EARLY_PHASE1Recruiting
36 participants
Started: Dec 1, 2024 · Completed: Apr 5, 2027
NCT06393335Collaborator
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
EARLY_PHASE1Recruiting
36 participants
Started: May 15, 2024 · Completed: Mar 15, 2026
Locations (1)
Headquarters
Shenzhen, China
Map
Loading map...